[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"late-life-depression-lld\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:late-life-depression-lld":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,73,103,132],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100644884","clinical-risk-score-prediction-for-risk-of-dementia-among-late-life-population-with-depression-100644884",false,"NCT07676851","Clinical Risk Score Prediction for Risk of Dementia Among Late-life Population With Depression","Development of a Clinical Risk Score Prediction Tool for 5-, 9-, and 13-year Risk of Dementia Among Late-life Population With Depression: a Longitudinal Cohort Study","Inclusion Criteria:\n\n* Adults aged ≥50 years.\n* A diagnosis of depression clearly recorded by a clinician in the electronic medical record at baseline (based on structured or unstructured diagnostic documentation formed through routine clinical practice).\n* Complete baseline electronic medical record data available, including at least demographic information (age, sex), clinical diagnoses, comorbidities, and medication records.\n* At least one follow-up record available in the electronic medical record system to enable determination of incident dementia outcomes.\n* Informed consent provided for the use of routine medical data for this research analysis.\n\nExclusion Criteria:\n\n* Any type of dementia diagnosis recorded in the electronic medical record at baseline (including Alzheimer's disease, vascular dementia, and other types of dementia).\n* Medical record documentation indicating that the diagnosis of dementia preceded the diagnosis of depression, or an inability to clearly determine the chronological order of the two diagnoses.\n* Presence of other neurological diseases at baseline that may independently cause severe cognitive impairment (e.g., Parkinson's disease, multiple sclerosis, brain tumor, normal pressure hydrocephalus).\n* Missing key baseline electronic medical record data that would preclude subsequent risk model analysis.\n* Incomplete follow-up information or inability to clearly confirm incident dementia outcomes through the electronic medical record system.\n* Refusal to participate in the study or withdrawal of informed consent.",true,"ALL","50 Years",{"count":20,"type":21},44,"ESTIMATED","13 Years","OBSERVATIONAL","The goal of this observational study is to learn about the ability of a point risk score prediction model, developed using electronic medical record data, to predict the risk of progression from geriatric depression to dementia in older Chinese adults. The main questions it aims to answer are:\n\nDoes a higher point risk score increase the risk of developing dementia in older adults with depression?\n\nWhat is the accuracy of the point risk score prediction model in identifying individuals at high risk of dementia among older adults with depression?\n\nParticipants will receive their usual medical care as they normally would. No new treatments, tests, or procedures will be performed specifically for this study. The research team will collect data from their electronic medical records, including depression diagnoses, dementia diagnoses, comorbidities, medication records, and follow-up information. The point risk score will be calculated based on these routinely collected clinical data.",[26,27,28,29,30,31,32,33,34],"Alzheimer Dementia (AD)","Dementia","Late Life Depression (LLD)","Risk Scores","Prediction","Chinese Population","Obs e r","Observational Cohort Study","External Validation","RECRUITING","2026-06-24",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":39},"2006-06-01",{"date":43,"type":21},"2030-06-30",{"name":45,"class":46},"Second Affiliated Hospital of Nanchang University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":47},"100641092","tdcs-for-late-life-depression-100641092","NCT07657234","tDCS for Late-Life Depression","High-Dose Spaced Bilateral tDCS for Late-Life Depression: Open-Label Pilot Study","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n1. age 60 years or older;\n2. diagnosis of unipolar major depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by the Mini International Neuropsychiatric Interview (MINI);\n3. score of 17 or higher on the 17-item Hamilton Depression Rating Scale (HDRS-17) at screening;\n4. stable antidepressant regimen for at least four weeks prior to enrollment, if applicable;\n5. capacity to provide informed consent;\n6. Clinical Dementia Rating scale of 0 or 0.5.\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria will be excluded:\n\n1. contraindications to tDCS including metallic cranial implants, skin conditions at electrode sites (eczema, open wounds, burns, lesions), or history of adverse reaction to tDCS;\n2. contraindications to magnetic resonance imaging (MRI) including pacemaker, cochlear implants, ferromagnetic implants, or claustrophobia;\n3. history of seizures or epilepsy;\n4. bipolar disorder, psychotic disorders, or severe personality disorder;\n5. dementia or MoCA score below 17;\n6. substance use disorder within the past six months;\n7. neuromodulation treatment including electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), tDCS, or vagus nerve stimulation (VNS) within the past six months;\n8. active suicidal ideation with plan or intent requiring a higher level of care;\n9. concurrent use of medications that substantially lower seizure threshold;\n10. pregnancy.","60 Years",{"count":57,"type":21},20,"INTERVENTIONAL",[60],"NA","The purpose of this research study is to determine the effectiveness of Transcranial direct current stimulation (tDCS) therapy in the treatment of participants with Late-life depression (LLD).\n\nThe study will evaluate feasibility, safety, and tolerability of high-dose (6mA) bilateral tDCS delivered as three daily sessions, 3 times a week, for 3 weeks in older adults (60 y\u002Fo and older) with late-life depression.",[28],"NOT_YET_RECRUITING","2026-06-12",{"date":66,"type":39},"2026-06-18",{"date":68,"type":21},"2026-08",{"date":70,"type":21},"2027-09",{"name":72,"class":46},"Andre Russowsky Brunoni",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":58,"phases":82,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100638441","phase-3-lumateperone-for-late-life-depression-100638441","NCT07623135","Lumateperone for Late-Life Depression","IRL Grey-C","Inclusion Criteria:\n\n* Age \\>=60\n* Current unipolar non-psychotic major depression determined by SCID-5\n* MADRS score \\>=20 at screening and \\>=18 at baseline\n* Treatment-resistance defined as documented history of non-response to at least two oral medications of adequate dose and duration in this episode or previous episode, OR clinician determination that treatment augmentation is appropriate\n* Currently taking oral antidepressant prescribed at least minimum therapeutic dose and for at least six weeks duration\n* MMSE score of \\>\u002F=24\n\nExclusion Criteria:\n\n* Dementia\n* High risk for suicide, defined as a 4 or 5 on C-SSRS (indicating active suicidal ideation with current or recent intent or plan), and unable to be managed safely in the clinical trial. Urgent psychiatric referral will be made in these cases.\n* High risk alcohol use: defined as a score of 6 or more on the AUDIT-C\n* Medically inappropriate for participation as determined by PIs.",{"count":81,"type":21},100,[83],"PHASE3","The purpose of this research study is to examine how well a medication called lumateperone (Caplyta) works to relieve depression in older adults with treatment-resistant depression. Lumateperone (Caplyta) is approved by the U.S. Food and Drug Administration to treat Major Depressive Disorder in adults who are also taking another antidepressant medication. This study will compare lumateperone (Caplyta) to placebo (a sugar pill without medication).",[86,28,87],"Treatment Resistant Depression (TRD)","Depression \u002F Major Depressive Disorder",[89,90,91,92],"Late life depression treatment","Treatment resistant depression in older adults","major depression","lumateperone","2026-05-28",{"date":95,"type":39},"2026-06-03",{"date":97,"type":21},"2026-06",{"date":99,"type":21},"2028-06",{"name":101,"class":46},"Eric Lenze",2,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":58,"phases":112,"briefSummary":113,"conditions":114,"keywords":118,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":102},"100581750","accelerated-vs-conventional-theta-burst-stimulation-for-late-life-depression-100581750","NCT06854367","Accelerated vs. Conventional Theta Burst Stimulation for Late-life Depression","ACT-LLD","Inclusion Criteria:\n\n1. are voluntary and competent to consent to treatment\n2. are an outpatient\n3. are ≥ 60 years old\n4. have a Mini International Neuropsychiatric Interview (MINI 7.0) confirmed diagnosis of MDD, with a current MDE\n5. have failed to achieve a clinical response to an adequate dose of an antidepressant based on an Antidepressant Treatment History Form (ATHF) score of ≥ 3 in the current episode or have failed to tolerate two separate trials of an antidepressant\n6. have a score ≥ 10 on the Patient Health Questionnaire (PHQ-9)\n7. have had no increase or initiation of any antidepressant or antipsychotic medication in the 4 weeks prior to screening\n8. are able to adhere to the treatment schedule\n9. pass the TMS adult safety screening (TASS) questionnaire\n\nExclusion Criteria:\n\n1. have a Mini International Neuropsychiatric Interview (MINI 7.0) confirmed diagnosis of substance dependence or abuse within the last 3 months\n2. have a concomitant major unstable medical illness as determined by one of the study physicians\n3. have active suicidal intent\n4. have presumed or probable dementia or clinical evidence of dementia as assessed by Short Blessed Test score ≥ 10\n5. have a lifetime MINI diagnosis of bipolar I or II disorder, or primary psychotic disorder\n6. have current psychotic symptoms\n7. have a diagnosis of obsessive compulsive disorder, post-traumatic stress disorder (current or within the last year), anxiety disorder (generalized anxiety disorder, social anxiety disorder, panic disorder), or dysthymia, assessed by a study investigator to be primary and causing greater impairment than MDD\n8. have a diagnosis of any personality disorder as assessed by a study investigator to be primary and causing greater impairment than MDD\n9. did not respond to a course of ECT in the current depressive episode\n10. have received rTMS in the current episode; patients who have had rTMS in a previous episode would be eligible\n11. have a history of a primary seizure disorder or a seizure associated with an intracranial lesion\n12. have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed\n13. have an implanted electronic device that is currently in function such as a defibrillator\n14. have a non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview)\n15. have clinically significant laboratory abnormality, in the opinion of a study investigator\n16. currently take more than lorazepam 2 mg daily (or equivalent) or any dose of an anticonvulsant\n17. if participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study",{"count":111,"type":21},280,[60],"The purpose of this trial is to compare the treatment efficacy (improvement in depressive symptoms) of accelerated TBS protocol (where participants receive multiple TBS treatments daily) to conventional TBS protocol (where participants receive a single TBS treatment daily) in late life depression. In addition, the study also aims to determine if specific patterns of stimulation are more or less effective. To do this, all participants will receive active treatments, but some of the participants in this study will receive accelerated TBS and some will receive once daily TBS.",[28,115,116,117],"Depression - Major Depressive Disorder","Depressive Disorder, Treatment-Resistant","Mood Disorders",[119,120,121,122],"Brain stimulation","rTMS","Theta burst stimulation","Accelerated theta burst stimulation","2026-01-27",{"date":125,"type":39},"2026-01-28",{"date":127,"type":39},"2025-03-27",{"date":129,"type":21},"2029-12",{"name":131,"class":46},"Centre for Addiction and Mental Health",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":140,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":102},"100242446","characterizing-cognitive-decline-in-late-life-depression-the-adni-depression-project-100242446","NCT02434393","Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project","Characterizing Cognitive Decline in Late Life Depression: The Alzheimer's Disease Neuroimaging Initiative - Depression Project","ADNI-D","Inclusion Criteria:\n\n1\\. Individual participated in original Characterizing Cognitive Decline in Late Life Depression study or Multimodal MRI Characteristics of Psychotherapy Response in Late Life Depression Study.\n\nExclusion Exceptions:\n\n1. Antidepressant medication treatment is allowed only if the medication dose is stable for 4 weeks prior to the MRI scan.\n2. Psychotherapy interventions is allowed only if they have completed at least 4 weeks of individual or group psychotherapy intervention prior to the MRI scan.\n3. Participants taking cognitive enhancing medications will be able to enter the study.","65 Years",{"count":142,"type":21},120,"The purpose of this research study is to characterize the mechanisms contributing to cognitive impairment and accelerated cognitive decline in Late Life Depression (LLD).\n\nThis is a non-randomized, observational, non-treatment study that originally launched in 2015, enrolling 133 participants. From the originally enrolled participants, the continuation of the ADNI-D study will enroll 120 participants which will include following participants from the original (parent) protocol and enrollment of new participants for a period of 30 months. Data from an additional 300 non-depressed subjects will be used from ADNI studies for comparison.\n\nDepression history, symptom severity and health information will be collected at the initial visit to determine eligibility. An magnetic resonance imaging (MRI) scan, as well as amyloid (florbetapir) and tau (flortaucipr) positron emission tomography (PET) imaging will be conducted at San Francisco VA. Collection of plasma and serum for biomarkers, clinical assessments and cognitive assessments will be conducted at two time points. Blood samples will also be collected for genetic analysis.",[145,28],"Major Depression",[147,148,149,150,151],"Depression","Late Life Depression","LLD","amyloid imaging","biomarkers","2025-11-21",{"date":154,"type":39},"2025-11-25",{"date":156,"type":39},"2015-03-04",{"date":158,"type":21},"2027-05",{"name":160,"class":46},"University of Southern California"]